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Abstract
One of the most important events in the posthematopoietic stem cell transplantation is 
the immune system reconstitution—a process characterized by a considerable dynamic. 
During this period, patients are exposed to different life threatening complications. In 
this chapter, we consider chimerism levels in relation to the conditioning regimens and 
disease type. Furthermore, the predictive role of chimerism analysis as an important 
method in monitoring the early diagnosis of graft versus host disease (GVHD), minimal 
residual disease (MRD), graft failure or rejection, and disease relapse has been discussed.
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1. Introduction
In March 1969, Prof. Thomas and his team performed the first transplantation of hemato-
poietic stem cells (HSCs). Since then, the transplantation of bone marrow or peripheral stem 
cells has become a routine method for treatment of a number of malignant and nonmalig-
nant hematologic diseases [1–6]. Allogeneic stem cell transplantation is effective in restoring 
normal hematopoiesis and is a preferred therapeutic method for malignant diseases of the 
blood, due to its graft-versus-leukemia (GVL) effect. This effect is mainly due to donor T cells 
that exhibit immunoreactivity against the minor histocompatibility antigens (mHags) of the 
recipient or epitopes specific for leukemic cells. The immune system recovery after allogeneic 
hematopoietic stem cells transplantation is of crucial importance during the postoperative 
period. This process lasts for months to years and depends mainly on the ability of the donor 
hematopoietic stem cells to take over the recipient cells.
© 2018 The Author(s). Licensee IntechOpen. This chap er is distributed under the terms of h  reative
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The determination of the genetic origin of hematopoiesis is referred to as chimerism analysis. 
The term "chimera" was introduced in medicine by Anderson and coworkers [7] in 1951, and 
in transplantology—by Ford [8] in 1956. It is used for people who have cell populations from 
different individuals of the same or a different type that arise occasionally during pregnancy 
or blood transfusions or are targeted—by transplantation of tissues, organs, and cells. The 
term chimerism refers to the coexistence of cells from two different organisms in a body.
Each stage of the transplant process potentially exposes the patient to complications and life-
threatening events; this is largely due to a lack of understanding of the mechanisms of engraft-
ment, as well as the genetic differences that exist between donor and recipient. Additional factor 
for consideration is the sensitivity of the methods used. The most widely used one—PCR-STR, 
is thought to have 1–5% sensitivity. Factors, such as type and stage of disease, patient age, donor 
type, HLA compatibility, number of transplanted CD34+ cells, graft T cell depletion, and many 
others, influence the postSCT immune reconstitution, as well as all subsequent complications.
The recovery of hematopoiesis depends mainly on the possibility of the donor hematopoietic 
stem cells to generate progenitor cells and repopulate the bone marrow niches. It creates a 
dynamic donor-recipient chimera, the exploration of which—qualitatively or quantitatively, has 
become an important component of the posttransplant monitoring of the patients. Chimerism 
is an important indicator for relapse, graft rejection, minimal residual disease (MRD), and graft 
versus host disease (GVHD). The presence of persistent or emerging recipient cells could mean 
surviving leukemic cells that could lead to a recurrence of a malignant branch by inhibiting 
immunocompetent donor cells. Therefore, the accurate assessment of chimerism in the patient’s 
blood or bone marrow provides important information about the engraftment process and aids 
in providing a more adequate treatment to the recipient. Initially, full donor hematopoiesis was 
thought to be essential for the survival of the graft after allogeneic stem cell transplantation [9], 
but in recent years it became clear that posttransplantation chimerism is a dynamic process, and 
patients with full donor chimerism (FDC) in a posttransplant period may subsequently develop 
mixed chimerism and vice versa—patients with mixed can develop complete chimerism.
2. Chimerism and different therapeutic strategies
Patients undergoing allogeneic SCT are given chemotherapy alone or in combination with 
radiotherapy prior to reinfusion of blood or a bone marrow graft. In autologous transplanta-
tions, the conditioning aims to eradicate tumor cells, whereas in allogeneic transplantations, 
it aims to immunosuppress the recipient (for the purposes of preventing graft rejection), pro-
vide better control of possible GVHD, eradicate tumor cells (which correlates mainly with the 
intensity of the regimen used), and allow immune reconstitution. There are some exceptions, 
like recipients with severe aplastic anemia or those with severe combined immunodeficiency 
who do not require full immune system eradication.
Treatment with chemotherapy or radiation therapy results in severe depletion of all hemato-
poietic cells of the immune system. Both alkylating chemotherapeutic agents and irradiation 
target highly proliferative cells [10–12], including developing and naïve lymphocytes, making 
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them particularly depleted following treatment [13]. Conditioning regimens cause neutrope-
nia, which are likely to last up to approximately 30 days depending on the source of stem cells 
[14]. Delayed recovery following immunodepletion is associated with a high degree of morbid-
ity and mortality [13, 15, 16]. Lymphoid recovery is critically dependent on primary immune 
system organs—the younger the patient, the faster the recovery of CD4+ T cells, B cells, and 
NK cells [17–20]. Recovery of NK cells after HSCT depends on an expansion of the cytokine-
producing CD56bright NK cell subset. Initial recovery of the T cell compartment relies on the 
peripheral expansion of memory T cells, driven by cytokines and the presence of alloreactive 
antigens [14]. Interestingly, CD8+ T cells recover at similar rates in young and aged patients, 
which could be due to extrathymic clonal expansion [20–23]. The recovery of B cells takes 
longest time—up to 2 years and is preceded by expansion of transitional CD19+CD24++CD38++ 
B cells [14]. Furthermore, immunodepletion from pretransplant conditioning causes enhanced 
senescence of the hematopoietic system coupled with an upregulation in the cyclindependent 
kinase inhibitors p19Arf and p16ink4A mimicking some of the age-related effects [24, 25].
With the development of less intensive conditioning regimens, the frontiers of hematopoietic 
stem cell transplantations have become even broader covering more diseases and more people 
becoming eligible for this treatment. The myeloablative regimens (MAs) are designed to fully 
eradicate the host immune system and facilitate the engraftment of donor cells. In contrast, 
reduced-intensity conditioning (RIC) and nonmyeloablative (NMA) regimens aim to suppress 
the immune system in view of preventing donor cell rejection rather than ablate it. Protocols 
using lower intensity conditioning regimens have been developed to treat hematological 
disorders in patients with medical comorbidities or elderly people who are not considered 
appropriate candidates for more intense and toxic conditioning. Thus, the duration of cytope-
nia is shorter and initial mixed donor chimerism (DC) is more likely to occur in those patients.
In 2009, Bacigalupo et al. published a report proposing a categorization of conditioning regi-
mens into three categories—myeloablative conditioning, reduced-intensity conditioning, and 
nonmyeloablative conditioning. These categories were distinguished on the basis of cytopenia 
duration and the need of stem cell support [26]. The terminology reflects the early regimen-
related toxicity to the host bone marrow cells, but not the biological effect of the transplant.
 - Myeloablative conditioning regimens
The MA protocols include administration of high doses of total body irradiation (TBI) and/or 
alkylating agents, which do not allow autologous hematologic recovery and should benefit 
a faster donor cell engraftment. Since it is unlikely to fully eradicate a person’s immune sys-
tem, the term myeloablation should be considered as an operational definition, indicating a 
regimen usually causing an irreversible pancytopenia [26]. The myeloablative conditioning of 
patients results in higher transplant-related mortality (TRM) and higher frequency of GVHD, 
compared to other protocols.
 - Reduced-intensity conditioning regimens
RIC regimens are considered an intermediate category of regimens, which cannot be clas-
sified as either NMA or MA—they cause cytopenia that may be prolonged, but the dose of 
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alkylating agents or TBI is reduced by at least 30%, as compared to MA, and they do require 
stem cell support [26].
 - Nonmyeloablative conditioning regimens
NMAs typically cause minimal cytopenia—they do not require stem cell support, but are 
immunosuppressive to the extent that, when followed by G-CSF mobilized peripheral blood 
stem cells (PBSC), they usually result in full donor cell engraftment. According to Bacigalupo 
et al., the NMA regimens are more “immune-ablative” than myelo-ablative [26]. The NMA 
conditioning results in lower TRM, as compared to MA but requires a larger amount of donor 
cells to facilitate a full replacement of the recipient’s hematopoiesis [27, 28]. Acute GVHD 
after NMA is delayed and may develop after day +100, at a time when chronic GVHD is 
usually diagnosed after MA regimen. GVHD remains a significant cause of morbidity and 
mortality after the application of both MA and NMA [29].
Many studies address the importance of chimerism monitoring after allo-SCT, but the data 
are controversial [30–36]. Moreover, chimerism monitoring in patients with MA condition-
ing is considered to be less informative and unnecessary, since the aggressive pretransplant 
preparation is thought to result in irreversible pancytopenia and achievement of stable full 
donor chimerism [30, 37, 38]. The chimerism status seems to be even more complicated as 
new data show the vague borders between the postSCT effects of the different conditioning 
protocols [31, 39, 40].
The aggressive pretransplant therapy is more effective against the disease, but its use is lim-
ited to younger and healthier patients who are able to tolerate concomitant toxicity. MA con-
ditioning aims to facilitate normal hematopoietic reconstitution with FDC by day +30, after 
allo-SCT. In unmanipulated grafts, chimerism analysis shows mostly FDC, as its early estab-
lishment may be an indication of GVHD. Mixed chimerism is more likely to be observed 
in patients who had received T cell-depleted graft. T cell depletion is used to reduce the 
frequency of GVHD—Mickelson et al. showed a significantly increased risk of developing 
acute or chronic GVHD in patients who reached levels of donor chimerism in T cells >90% 
(HR = 1.92, P = 0.08 and HR = 2.26, and P = 0.07, respectively) [31]. Moreover, speed and extent 
of donor chimerism have been shown to be influenced by additional factors including pri-
mary diagnosis and previous treatment [37].
2.1. Investigation of chimerism in myeloablative HSCT
From a historical point of view, ablative chemotherapy and total body irradiation were 
accepted as a treatment for elimination of malignant cells and targeting immunosuppression 
with view of facilitating donor cell engraftment. High dosage protocols aiming to achieve 
antileukemic effect are still in use for patients with aggressive malignant diseases. The main 
treatment includes cyclophosphamide and TBI or busulfan (BU), and more often a combina-
tion of busulfan and fludarabine at dosages eliminating all myeloid cells [41]. The aggres-
sive pretransplant conditioning is very effective for the primary disease, but it is limited to 
younger patients who are able to tolerate treatment-related toxicity. Myeloablative condition-
ing schemes could facilitate reconstitution of hematopoiesis with a complete lymphocyte chi-
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merism at day 30 after HSCT. In such type of HSCT, cases of GVHD are more frequent, while 
relapses have been rarely observed. Chimerism analysis shows complete donor chimera [37]. 
In 50–100% of the patients transplanted with T cell-depleted bone marrow grafts, mixed chi-
mera have been observed. In these transplant procedures very often donor-lymphocyte infu-
sion is performed, especially in CML patients.
2.2. Investigation of chimerism in nonmyeloablative/reduced-intensity HSCT
One of the main factors allowing increase in the number of HSCT is the development of non-
myeloablative conditioning and reduced-intensity conditioning regimens. The introduction 
of these protocols is related to the lower treatment-related mortality, allowing the application 
of HSCT as a treatment for elderly people and patients in a severe clinical condition. Another 
substantial advantage of these protocols is the better immune reconstitution due to the lower 
degree of thymus injury, despite the fact that studies showed similar outcomes for HSCT. This 
allows better regeneration of naïve T cells and proliferation of immune-competent cells of the 
recipient, which have survived after conditioning. The majority of RIC protocols are based on 
a combination of purine analogs, usually fludarabine with alkylating agents, such as busul-
fan or cyclophosphamide, and represent a different intensity of myelosuppression [42–44]. 
Another approach is to use low doses of TBI, alone or in combination with fludarabine [45]. 
This approach relies on the GVL effect and is associated with minimal toxicity. Several stud-
ies have shown the association between patient conditioning and posttransplant chimerism 
levels [46, 47].
Unlike HSCT with myeloablative conditioning, nonmyeloablative conditioning is related to a 
mixed chimerism [6]. Additionally, the probability to develop aGVHD is lower, while prob-
ability to develop cGVHD is comparable for both conditioning protocols. The immunobiol-
ogy of allo-SCT after NMA conditioning differs from that after MA mainly by the release 
of less inflammatory cytokines. Tissue damage caused by myeloablation is translated into 
proinflammatory cytokines that are supposed to provide a milieu for the development of 
GVHD. As a result, aGVHD after NMA is delayed and may develop after day +100, remaining 
a significant cause of morbidity and mortality in NMA SCT patients. Mixed chimerism does 
not mean grim prognosis but could be associated with increased risk of relapses.
Relatively decreased aGVHD after RIC HSCT could be explained by a combination of pretrans-
plant conditioning and initial mixed chimerism that could contribute to the development of 
tolerance [29, 45]. Some patients demonstrate late development of aGVHD that coincides with 
the transition from mixed to complete donor T cell chimera [46]. In patients who do not develop 
GVHD, donor lymphocyte infusion could be performed in order to achieve complete chimera 
and GVL effect. Therefore, in HSCT with nonmyeloablative conditioning, it is very important 
to monitor chimerism level in order to assess correctly the need of donor lymphocyte infusion 
and the effect of this treatment [37]. Lower levels of T and NK cells in the first 30 days following 
HSCT are associated with increased risk of graft rejection. Granulocyte and monocyte chime-
rism levels have limited relevance for graft rejection [46]. In contrast, high levels of donor T cells 
are predictive for development of aGVHD grade 2–4 [31, 46, 48]. Additionally, levels above 90% 
donor T and/or NK cells are associated with antitumour response and disease-free survival [46, 
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49]. Similar results have been reported by Mohty et al. (n = 102) [48]. In contrast, some studies 
do not reveal an association between the level of donor T lymphocytes and the development 
of GVHD [50, 51]. In their study, Lim et al. showed that rapid conversion to complete donor 
chimera is associated with decreased overall survival and increased TRM when compared 
with persistence of mixed chimerism. No association with relapse frequency was observed 
[52]. Mixed chimera is related to better survival—this observation could be explained by the 
persisting recipient cells, associated with resistance to infections and overall survival [52, 53]. 
Patients with low absolute count of dendritic cells, one month following HSCT, have a higher 
TRM (60% versus 12%, P < 0.02) and decreased overall survival (15% versus 45%, P < 0.002) [54]. 
There is also an association between decreased CD16+ dendritic cells and increased infection-
related mortality (50% versus 0%, P < 0.05). The possibility that the infection itself is likely to 
decrease the number of these cells cannot be excluded [54].
2.3. Chimerism following donor lymphocyte infusion (DLI)
Donor lymphocyte infusion is a new therapeutic strategy, applied mainly in cases of nonmy-
eloablative, T cell-depleted myeloablative HSCT, or haploidentical transplantations due to its 
GVL effect. These patients have delayed immune reconstitution, increasing the risk of disease 
relapse. Application of standard DLI is limited due to GVHD and aplasia. New protocols using 
G-CSF-stimulated blood progenitor cells, allodepleted donor T cells and mHag-specific CD8+ 
cytotoxic T lymphocytes have been currently developed allowing wider application of this type 
of therapy. A limitation of the latter is estimating the right time for DLI. Lymphocyte infusions 
in the early relapses are associated with favorable outcome [55, 56]. Therefore, chimerism should 
be monitored regularly in order to detect recipient-specific hematopoiesis [6, 57, 58]. Infused 
lymphocytes are sensitized by surface antigens that are associated with leukemia or polymor-
phic minor histocompatibility antigens, which are expressed by the leukemic cells. This induces 
their transformation into cytotoxic lymphocytes killing cancer cells. DLI is most effective in 
patients with CML (approximately 75%), which could be explained by the antigen-presenting 
cells found in malignant clones. This therapy is not effective in patients with AML or multiple 
myeloma. The development of new therapeutic protocols has decreased aplasia and GVHD.
3. Chimerism in nonmalignant diseases
Currently, a major part of inherited or acquired nonmalignant diseases, such as thalassemia, 
aplastic anemia, and immune deficiencies, can be successfully treated by HSCT. The aim 
of such type of transplantation is to achieve stable engraftment, enabling hematopoiesis, 
enzyme activity, or immune competence. Therefore, establishment of complete donor chi-
mera is not necessary and the recipient can be conditioned by nonmyeloablative therapy. This 
results more often in the establishment of mixed chimera, increased risk of graft rejection, 
and decreased risk of GVHD. On the other hand, rapid development of complete chimera 
in NK and T cells is very important for the successful engraftment, although it increases the 
frequency of acute GVHD [59–61].
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4. Chimerism in malignant diseases
Monitoring MRD and chimerism levels in patients with malignant diseases is very important. 
Allogeneic HSCT is an effective therapy in both low- and high-risk CLL. The analysis of 44 
high-risk patients with 17p deletion and RIC transplantation showed a four-year cumulative 
frequency of disease progression of 34% [62]. Establishment of T cell mixed chimera 90 days 
following transplantation and chemorefractory disease are associated with increased risk of 
disease progression. Establishment of complete donor chimera and lack of MRD are associ-
ated with prolonged DFS. Limited data on the relapse outcome in CLL are available and some 
patients have positive response to DLL treatment and immunosuppression withdrawal. A 
better response has been observed in patients with 100% donor T cells. Many studies have 
shown that conversion from mixed to complete donor chimera predicts development of 
GVHD [46, 62–64].
In patients with acute leukemia (AML and ALL), mixed chimera may be associated with 
increased risk of graft rejection. A greater risk has been demonstrated in patients with high 
levels of residual cells and/or rapid increase of recipient cells [2, 4, 5]. Monitoring of the 
level of expression of WT1 and the kinetics of nonseparated CD34 chimerism allows early 
detection of relapse in MDS and AML patients. In patients with stable CD34+ levels and 
WT1 expression under predefined cut off, relapse could be excluded within the following 
28 days [34, 65, 66].
Establishment of mixed chimera can be associated with many factors such as condition-
ing intensity, T cell-depleted grafts, CD34 cell dosage, techniques used for monitoring, and 
primary disease. Due to the dynamics in chimerism development, chimerism should be 
monitored at shorter intervals, especially in the first 1–2 months following transplantation 
when the risk of rejection is higher. In the early posttransplant period, the persistent mixed 
chimera could indicate graft rejection or early relapse. On the other hand, the increased 
number of recipient cells at a later stage after transplantation is associated with a relapse or 
late rejection.
Due to its low sensitivity of about 1%, chimerism analysis could be used as a prognostic rather 
than an indirect indicator for MRD. With the introduction of RQ-PCR technique, the sensitiv-
ity of chimerism monitoring has improved to 0.1%, resulting in improvement of its prognostic 
value for MRD detection.
5. Chimerism analysis: technical considerations
Expanding the curability of hematological diseases with stem cell transplantation, as well as 
introducing new conditioning protocols allows more patients to be eligible for this treatment. 
This raises the need for better posttransplant chimerism monitoring, since the different quan-
titative or semiquantitative methods have their advantages and disadvantages. While the sig-
nificance of the absolute value is still under discussion, the relative changes in engraftment 
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kinetics are a reliable sign for acceptance or rejection of the graft. This, in its turn, requires 
a determination of the factors intrinsic for the platform, which may influence the observed 
changes in chimerism result [67, 68]. Some of the most important characteristics of the methods 
for postSCT chimerism monitoring are their sensitivity, precision, and reproducibility [69–71].
Investigating microsatellites (STR) and minisatellites (VNTR) is considered the most sensitive and 
informative technique to study the levels of chimerism after HSCT. Micro (2–5 bp) and minisatel-
lites (9–80 bp) are tandemly repeated blocks of noncoding DNA that are widespread throughout 
the human genome. The repeat-pattern of these blocks varies greatly among individuals in a pop-
ulation. There is a large number of STR (short tandem repeats) systems that have been mapped 
throughout the human genome, and they are found on almost every chromosome (Table 1).
Chromosome STR markers RFLP-based VNTR markers Other PCR-based 
markers
1 F13B, RENA4, D1S1171, D1S1627, 
D1S1656, D1S1677, D1S2142, and 
D1GATA113
D1S7 and D1S339 D1S80
2 APOB, TPOX, D2S410,  
D2S441, D2S436, D2S1242, D2S1338, 
D2S1360, D2S1772, and D2S1776
D2S44 ApoB
3 ACPP, D3S1349, D3S1352, D3S1358, 
D3S1359, D3S1545, D3S1744, D3S3053, 
and D3S4529
4 FABP, FGA (FIBRA), GABARB15, 
D4S2364,  
D4S2366, D4S2368, and D4S2408
D4S139 GC (PM) and GYPA 
(PM)
5 CSF1PO, D5S373, D5S815, D5S818, and 
D5S2500
D5S110
6 F13A1, FOLP23, SE33 (ACTBP2), D6S366, 
D6S474, D6S477, D6S502, D6S965, 
D6S1017, and D6S1043
D6S132 DQa
7 D7S460, D7S809, D7S820, D7S821, 
D7S1517, D7S1520,  
and D7S3048
D7S21, D7S22, D7S467 D7S8 (PM)
8 LPL (LIPOL), D8S306,  
D8S320, D8S323, D8S344, D8S347, 
D8S639, D8S1132, D8S1115,  
and D8S1179
9 D9S52, D9S302, D9S304, D9S925, 
D9S1122, and  
D9S2157
10 D10S89, D10S1248, D10S1435, D10S2325, 
and D10S2326
D10S28
11 APOAI1, TH01 (TC11), UGB, D11S488, 
D11S554, and D11S4463
HBGG (PM)
12 CD4, PLA2A1, VWA, D12S67, D12S391, 
D12S1090, and D12ATA63
D12S11
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The method is semiquantitative and has a moderate level of sensitivity—1–5%; neither 
gender nor HLA compatibility of donor and recipient can influence its informativity; it 
requires a very small number of cells, which makes it applicable in the first postSCT days. 
Chromosome STR markers RFLP-based VNTR markers Other PCR-based 
markers
13 D13S308, D13S317, and D13S1492
14 D14S306, D14S608, and D14S1434 D14S13
15 CYAR04 (P450), FES/FPS,  
Penta E, D15S659, and  
D15S822
16 D16S537, D16S539, and D16S3253 D16S85
17 D17S974, D17S976, and D17S1301 D17S79, D17S26 D17S5, YNZ22
18 MBP, D18S51, D18S535, D18S849, 
D18S853, and D18S1270
19 D19S253, D19S433 LDLR (PM)
20 D20S85, D20S161, D20S470, D20S482, and 
D20S1082
21 Penta D, D21S11, D21S1437, and 
D21S2055
22 D22S683 and D22S1045
X HPRTB, ARA, STRX1, DXYS156, 
DXS101, DXS981, DXS6789, DXS6795, 
DXS6797, DXS6800, DXS6801, DXS6803, 
DXS6807,DXS6809, DXS7130, DXS7132, 
DXS7133, DXS7423, DXS7424, DXS8377, 
DXS8378, DXS9895, DXS9898, DXS9905, 
DXS9908, DXS10011, GATA31E08, 
GATA165B12,  
and GATA172D05
Amelogenin
Y DYS19, DXYS156, DYS385 a/b, DYS388, 
DYS389 I/II, DYS390, DYS391, DYS392, 
DYS393, DYF406S1, DYS437, DYS438, 
DYS439, DYS444, DYS446, DYS447, 
DYS448, DYS449, DYS456, DYS458, 
DYS460, DYS461, DYS462, DYS463, 
DYS464 a/b/c/d, DYS481, DYS485, 
DYS495, DYS505, DYS508, DYS520, 
DYS522, DYS525, DYS531, DYS532, 
DYS533, DYS534, DYS540, DYS549, 
DYS556, DYS557, DYS570, DYS576, 
DYS578, DYS589, DYS594, DYS617, 
DYS635, DYS643, DYS724 (CD a/b), 
GATA-H4, and YCAII a/b
Amelogenin and 
Y-SNPs
mtDNA HV1 and HV2
Table 1. Chromosome location of mini- and microsatellites [72].
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Multiplex platforms use STR/VNTR (variable number tandem repeats) loci with identi-
cal amplification protocols and different allelic lengths, using fluorescently labeled prim-
ers. Due to its large size, VNTR more often showed discrepancies in the evaluation of 
chimerism between markers [73]. All loci are amplified together in a single PCR reac-
tion and amplification products are electrophoretically separated on an automated DNA 
sequencer—fragment analysis. Further analysis is carried out by specialized software. 
Microsatellites are more widely used, since they are polymorphic, more sensitive, faster 
to work with, and cheaper. Despite their excellent performance in forensic science, their 
application in the study of chimerism has its limitations. The most important one results 
from the very design of the platform—the amount of DNA is indirectly evaluated based 
on measurement of fluorescence during electrophoresis. The various fluorophores differ 
in their efficiency to emit light, and the platform has no internal calibration for measure-
ment. As a result, the measurement of one and the same absolute value of DNA will not 
be equally estimated in all loci. However, this fluorescence-based technology is considered 
the gold standard in the study of chimerism [58]. Another feature of the STR system is 
the presence of additional signals—stutter peaks, which are mainly n − 1 and to a lesser 
degree n + 1 signals [74, 75]. These artifacts are the result of slipped-strand mispairing 
during amplification. Their size depends on the size and type of the allele, and is in the 
range 2–13% of their respective base peaks. Stutter is less pronounced with larger repeat 
units (dinucleotides > tri- > tetra- > penta-). Longer repeat regions generate more stutter, 
and each successive stutter product is less intense. If stutter peaks match the correspond-
ing donor or recipient peaks, this would affect the estimate of chimerism. This is especially 
important at low levels of the host residual cells, which would hamper the assessment of 
minimal residual disease. In heterozygous loci, the two alleles should be equal in amount, 
but due to stochastic effects during PCR amplification, an imbalance in the two detected 
alleles is established—this is especially true when the amount of DNA being amplified is 
limited. Under conditions of extreme imbalance, one allele may “drop-out”.
6. Conclusion
Different protocols have been used to condition patients prior to HSCT. They differ from each 
other in intensity of myeloablation. Myeloablative conditioning is very aggressive and leads 
to high toxicity and TRM, so its application is limited to younger patients and patients in good 
medical condition. The risk of TRM decreases with time, although the causes for this are not 
fully understood. Most likely this is due to advances in technology for HLA typing, better 
understanding of the role of HLA compatibility, particularly with regard to unrelated donors, 
and better medical services for patients. Various conditioning protocols are deemed to have 
varying degrees of ablation of the recipient immune system resulting in different profiles of 
posttransplantation recovery.
The levels of chimerism after HSCT depend on a number of factors, including the intensity of 
pretransplant conditioning, the use of T cell-depleted grafts, the number of transplanted stem 
cells, the sensitivity of the technique used for detection and the interval of study, and as well 
as the type of the disease.
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The main objective in posttransplantation monitoring is early diagnosis of adverse events. Due 
to the dynamic nature of the development of chimerism, its monitoring should be carried out 
at short intervals, especially in the first 1–2 months after transplantation, when the risk of dis-
ease recurrence or graft failure/rejection is greatest. In the earliest posttransplantation period, the 
presence of persistent mixed chimerism or the disappearance of donor alleles are associated with 
both graft rejection and early relapse of the underlying disease. On the other hand, the increas-
ing number of recipient cells in the later periods after the transplantation is associated with 
upcoming relapse or late allograft rejection. The mechanisms that direct hematopoietic recovery 
toward one or another course are not yet fully understood. The analysis of chimerism kinetics 
allows early differentiation between the lack of engraftment and its delay, as well as early detec-
tion of patients at high risk of developing GVHD or susceptible to a relapse. In this context, the 
study of chimerism is undoubtedly an important method for monitoring the outcome of HSCT.
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